Browse the library
Articles
Follow a recurring series or browse every sourced analysis in publication order.
Regulatory Pulse
A weekly source-by-source scan of what changed in UK private clinic regulation — and what stayed the same.
1 article
Enforcement Watch
Rulings, investigations and enforcement patterns affecting UK private clinics, pharmacies and healthcare advertising.
4 articles
Scientific Digest
New clinical research and evidence interpreted through the lens of UK private clinic safety and regulation.
4 articles
Guides
Evergreen guides to UK clinic licensing, legislation, prescribing rules and regulatory responsibilities.
3 articles
Regulatory Updates
Material UK regulatory, policy and medicine-approval developments with direct relevance to private clinics.
2 articles
All articles
13 articles-
Private scripts surged 134% — CQC report
Weekly regulatory scan: CQC reports a 134% rise in private CBPM prescribing and records what changed across six UK regulatory sources.
-
Wegovy approved for liver disease: new clinic opportunity
The MHRA approved Wegovy to treat MASH liver disease. This update explains what it means for private clinics prescribing semaglutide.
-
PJ analysis: online pharmacy weight loss prescribing safety
Research on safety risks in online pharmacy weight-loss prescribing and how it connects to GPhC enforcement.
-
Major review confirms GLP-1 safety for weight loss
A Nature Medicine review of 56 trials covering semaglutide and tirzepatide, with implications for UK clinic prescribing.
-
New CQC Chair: what Sir Mike Richards means for clinics
Sir Mike Richards' appointment as preferred CQC Chair and what his regulatory track record signals for private clinics.
-
New study maps UK aesthetic medicine workforce
The first national workforce mapping study and what it adds to the case for cosmetic-procedure licensing.
-
GPhC finds weaknesses in weight-loss pharmacy safeguards
A GPhC review found weak risk assessments and inconsistent BMI checks in online pharmacies prescribing weight-loss medicines.
-
4.9 million UK adults have used GLP-1 drugs, study finds
New prevalence evidence on UK GLP-1 use and the implications for advertising enforcement and pharmacy safeguards.
-
Cosmetic procedure licensing UK: the complete guide
A sourced guide to Section 180, Scotland's law, the proposed three-tier system and the current UK licensing position.
-
ASA upholds Black Friday Mounjaro ad complaints
The ASA ruled against Juniper and Voy over Black Friday promotions for prescription-only weight-loss medicines.
-
Most clinic ads are breaking this rule
Recent ASA rulings reveal a recurring pattern in weight-loss advertising for prescription-only medicines.
-
ASA caught 900 weight-loss ad violations in one sweep
The ASA's monitoring found roughly 900 prescription-only medicine advertising violations from 38 advertisers.
-
Section 180: cosmetic procedure licensing UK explained
What Section 180 says, who it affects and where the cosmetic-procedure licensing scheme currently stands.